Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.48 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | NRP1 | O14786 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | RAMP3 | O60896 | 2/20 | 0.42 |
| ▸ | CALCR | P30988 | 2/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194515 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL21043608 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL1247799 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL7263725 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL12899263 | 1.00 | OPRM1 (0.48) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL12261069 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL13084631 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL14227389 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL12899266 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 | |
| SCHEMBL12237919 | 0.97 | GRB2 (0.50) | OPRM1OPRK1GRB2F2NRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395521-A1 | MICROBIOME REGULATORS AND RELATED USES THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-2235038-B1 | Tetrapeptide Combination | GKL BIOTEC AG (CH) | 2019-06-05 | — | — | EP | disclosed |
| US-20180296582-A1 | MICROBIOME REGULATORS AND RELATED USES THEREOF | HERCULES CAPITAL, INC. | 2018-10-18 | — | — | US | disclosed |
| EP-3285778-A2 | MICROBIOME REGULATORS AND RELATED USES THEREOF | Kaleido Biosciences, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9850274-B2 | Peptide combination | GKL-BIOTEC AG (CH) | 2017-12-26 | — | — | US | disclosed |
| WO-2016172658-A2 | MICROBIOME REGULATORS AND RELATED USES THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| EP-1289565-B1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS | BRACCO SUISSE SA (CH) | 2015-04-22 | — | — | EP | disclosed |
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | BRACCO SUISSE S.A. (CH) | 2012-12-13 | — | — | US | disclosed |
| US-8263739-B2 | also targeting tumor cells that express vascular endothelial growth factor neuropilin-1 receptor; radiotherapy; radiopharmaceuticals; treating angiogenesis | BRACCO SUISSE SA (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | BRACCO INTERNATIONAL B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
| US-7109167-B2 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO INTERNATIONAL B.V. (NL) | 2006-09-19 | — | — | US | disclosed |
| US-20060153775-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO INTERNATIONAL B.V. (NL) | 2006-07-13 | — | — | US | disclosed |
| EP-1289565-A2 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS | Bracco Research USA (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020147136-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | BRACCO SUISSE SA (CH) | 2002-10-10 | — | — | US | disclosed |
| WO-2001091805-A2 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS | BRACCO RESEARCH USA (US) | 2001-12-06 | — | — | WO | disclosed |
| US-4987237-A | Derivatives of monophosphoryl lipid A | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 1991-01-22 | — | — | US | disclosed |
| US-4786737-A | PREPARATION OF TUFTSIN AND LISINOPRIL | AJINOMOTO CO., INC. (JP) | 1988-11-22 | — | — | US | disclosed |
| US-4720554-A | Aromatic sulfonic acid salts of a proline derivative | AJINOMOTO CO., INC. (JP) | 1988-01-19 | — | — | US | disclosed |
| EP-0178845-A2 | Peptide-substituted heterocyclic immunostimulants | PFIZER INC. (US) | 1986-04-23 | — | — | EP | disclosed |
| EP-0157572-A2 | Acyltripeptide immunostimulants | PFIZER INC. (US) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060153775-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | VCAM1, FLT1, EDNRA | OPRM1 1803/4885OPRK1 1592/4885GRB2 756/4885 |
| US-20120315220-A1 | Compounds for Targeting Endothelial Cells, Compositions Containing the Same and Methods for Their Use | VCAM1, FLT1, EDNRA | OPRM1 1803/4885OPRK1 1592/4885GRB2 756/4885 |
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | VCAM1, FLT1, EDNRA | OPRM1 1803/4885OPRK1 1592/4885GRB2 756/4885 |
| US-20020147136-A1 | Compounds for targeting endothelial cells, compositions containing the same and methods for their use | VCAM1, FLT1, EDNRA | OPRM1 1803/4885OPRK1 1592/4885GRB2 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.